Compare Stocks → A new way to collect income from stocks (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEAMERICAN:ASTCVE:NZNYSE:RMP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASTAsterias Biotherapeutics$0.00$0.00$0.51▼$2.05$111KN/A136,653 shs1,000 shsNZNew Zealand EnergyC$1.15C$0.83C$0.30▼C$1.67C$9.57M2.96,488 shs6,500 shsRMPRice Midstream Partners$1,714.23$0.00$16.68▼$23.00N/AN/A495,689 shsN/AThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNZNew Zealand Energy0.00%+9.52%+43.75%+40.24%+1,337.50%RMPRice Midstream Partners0.00%0.00%0.00%0.00%0.00%Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANZNew Zealand EnergyN/AN/AN/AN/AN/AN/AN/AN/ARMPRice Midstream PartnersN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASTAsterias BiotherapeuticsN/AN/AN/AN/ANZNew Zealand EnergyN/AN/AN/AN/ARMPRice Midstream PartnersN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/ANZNew Zealand EnergyC$2.60M3.68C$0.38 per share3.00C$0.72 per share1.60RMPRice Midstream PartnersN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASTAsterias BiotherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ANZNew Zealand EnergyC$1.52MC$0.205.75∞N/A13.51%24.17%0.19%6/4/2024 (Estimated)RMPRice Midstream PartnersN/A$1.98865.77∞N/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASTAsterias BiotherapeuticsN/AN/AN/AN/AN/ANZNew Zealand EnergyN/AN/AN/AN/AN/ARMPRice Midstream Partners$1.220.07%N/A61.62%N/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASTAsterias BiotherapeuticsN/AN/AN/ANZNew Zealand Energy145.520.330.45RMPRice Midstream PartnersN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipASTAsterias BiotherapeuticsN/ANZNew Zealand EnergyN/ARMPRice Midstream Partners74.09%Insider OwnershipCompanyInsider OwnershipASTAsterias BiotherapeuticsN/ANZNew Zealand Energy42.69%RMPRice Midstream PartnersN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableASTAsterias BiotherapeuticsN/A55.66 millionN/ANot OptionableNZNew Zealand EnergyN/A8.32 millionN/ANot OptionableRMPRice Midstream PartnersN/AN/AN/AOptionableLEK, AST, NZ, GBP, and RMP HeadlinesSourceHeadlineHealthy chicken and ricebbc.co.uk - April 19 at 6:17 PMRotisserie Chicken Fried Ricetoday.com - March 14 at 7:30 PMSummit Midstream Partners LP (SMLP)uk.investing.com - February 26 at 7:37 PMLong-grain rice recipesbbc.co.uk - December 23 at 9:24 AMRice noodles recipesbbc.co.uk - December 15 at 5:27 PMIndia: Riceasiasociety.org - July 20 at 8:38 AMBrazilian rice exports booming; challenge for all three Mercosur partnersen.mercopress.com - May 30 at 1:24 PMWhy Magellan Midstream Partners Stock Is Rising Mondaymsn.com - May 17 at 9:38 AMVietnam's rice export turnover increases by 54.5% in first 4 months of 2023poandpo.com - May 16 at 8:37 AMBest Rice Cookersconsumerreports.org - May 13 at 3:28 PMHow much arsenic is in your rice?consumerreports.org - March 26 at 6:27 PMNiger Partners Chevron, Others to Boost Rice Productionthisdaylive.com - March 15 at 5:44 AMSummit Midstream Partners Stock (NYSE:SMLP), Quotes and News Summarybenzinga.com - March 1 at 8:11 AMDeclan Rice's potential Arsenal switch poses awkward reunion with former team-matemirror.co.uk - February 11 at 1:57 AMLCFE Onboard Imota Rice Receipts for Tradingthisdaylive.com - February 5 at 2:13 PMBrazilian rice exports jumped 85% during 2022 compared to 2021en.mercopress.com - January 25 at 6:55 PMRice types approved for GI statusbangkokpost.com - January 22 at 11:27 PMWhat’s the Difference Between Jasmine Rice and White Rice?healthline.com - January 21 at 5:01 PMDeclan Rice has told Erik ten Hag and Manchester United exactly what they wanted to hearmanchestereveningnews.co.uk - January 9 at 10:06 AMMartin Midstream Partnersforbes.com - January 5 at 7:51 AMRice Acquisition Corp. II: The Rice Brothers Have Another New SPAC And I'm Buyingseekingalpha.com - December 16 at 12:59 PMRice mandi pricescommodityonline.com - October 31 at 7:44 PMBUA Group Partners Kano Farmers on Rice Productionthisdaylive.com - October 19 at 6:01 PMBrazil, with Mercosur partners, plans to become a global rice exporting huben.mercopress.com - October 8 at 9:35 AMMedia Sentiment Over TimeTop HeadlinesFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentBreakout Alert: Coinbase's Consolidation Is About To EndApril 12, 2024 9:45 AMView Breakout Alert: Coinbase's Consolidation Is About To EndDisney Stock Catches 3 Upgrades In a Single WeekMarch 28, 2024 10:27 AMView Disney Stock Catches 3 Upgrades In a Single WeekBuy the Dip in Netflix Stock, It Won’t Last LongApril 19, 2024 8:32 AMView Buy the Dip in Netflix Stock, It Won’t Last LongDividend Aristocrat Fastenal Goes on Sale: Buy It While It’s DownApril 11, 2024 12:07 PMView Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s DownAll Headlines Company DescriptionsAsterias BiotherapeuticsNYSEAMERICAN:ASTAsterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.New Zealand EnergyCVE:NZNew Zealand Energy Corp., together with its subsidiaries, engages in the exploration and production of oil and natural gas in New Zealand. It holds interests in three petroleum mining licenses, one petroleum mining permit, and one petroleum exploration permit. The company has interests in TWN Petroleum Mining Licenses comprising Waihapa/Ngaere, and Tariki; Copper Moki petroleum mining permit; and Eltham Petroleum exploration permit. It also operates midstream assets. The company was founded in 2010 and is based in New Plymouth, New Zealand.Rice Midstream PartnersNYSE:RMPRice Midstream Partners LP owns, operates, develops, and acquires midstream assets in the Appalachian Basin. It operates in two segments, Gathering and Compression, and Water Services. Its natural gas gathering and compression assets consist of natural gas gathering and compression systems that serve producers in the dry gas core of the Marcellus Shale in southwestern Pennsylvania. The company also provides water services to support well completion activities, as well as to collect and recycle or dispose of flowback and produced water in Washington and Greene counties, Pennsylvania; and Belmont County, Ohio. Rice Midstream Management LLC serves as the general partner of Rice Midstream Partners LP. The company was founded in 2014 and is headquartered in Pittsburgh, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
